ES2426539B1 - Uso de la diaminooxidasa para el tratamiento o la prevención del trastorno por deficit de atencion con hiperactividad (adhd) - Google Patents

Uso de la diaminooxidasa para el tratamiento o la prevención del trastorno por deficit de atencion con hiperactividad (adhd) Download PDF

Info

Publication number
ES2426539B1
ES2426539B1 ES201230578A ES201230578A ES2426539B1 ES 2426539 B1 ES2426539 B1 ES 2426539B1 ES 201230578 A ES201230578 A ES 201230578A ES 201230578 A ES201230578 A ES 201230578A ES 2426539 B1 ES2426539 B1 ES 2426539B1
Authority
ES
Spain
Prior art keywords
diaminooxidase
adhd
prevention
treatment
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES201230578A
Other languages
English (en)
Other versions
ES2426539A1 (es
Inventor
Carlos DUELO RIU
Juan José Duelo Riu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Healthcare Espana SL
Original Assignee
Dr Healthcare Espana SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48539331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2426539(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dr Healthcare Espana SL filed Critical Dr Healthcare Espana SL
Priority to ES201230578A priority Critical patent/ES2426539B1/es
Priority to PT137262960T priority patent/PT2844277T/pt
Priority to CN201380020361.6A priority patent/CN104284672A/zh
Priority to DK13726296.0T priority patent/DK2844277T3/en
Priority to EP13726296.0A priority patent/EP2844277B2/en
Priority to HUE13726296A priority patent/HUE032712T2/en
Priority to US14/394,589 priority patent/US9795654B2/en
Priority to PL13726296T priority patent/PL2844277T5/pl
Priority to ES13726296T priority patent/ES2621706T5/es
Priority to RU2014140676A priority patent/RU2660344C2/ru
Priority to PCT/IB2013/053068 priority patent/WO2013156955A1/en
Priority to MX2014012636A priority patent/MX361227B/es
Publication of ES2426539A1 publication Critical patent/ES2426539A1/es
Publication of ES2426539B1 publication Critical patent/ES2426539B1/es
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03006—Amine oxidase (copper-containing)(1.4.3.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Uso de la diaminooxidasa para el tratamiento o la prevención del trastorno por déficit de atención con hiperactividad (ADHD).#La presente invención se refiere al uso de la diaminooxidasa para la fabricación de una composición para la fabricación de una composición para el tratamiento o la prevención del trastorno por déficit de atención con hiperactividad (ADHD).

Description



imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10

Claims (1)



  1. imagen1
ES201230578A 2012-04-18 2012-04-18 Uso de la diaminooxidasa para el tratamiento o la prevención del trastorno por deficit de atencion con hiperactividad (adhd) Active ES2426539B1 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
ES201230578A ES2426539B1 (es) 2012-04-18 2012-04-18 Uso de la diaminooxidasa para el tratamiento o la prevención del trastorno por deficit de atencion con hiperactividad (adhd)
US14/394,589 US9795654B2 (en) 2012-04-18 2013-04-18 Diamine oxidase for use in the treatment or prevention of attention deficit hyperactivity disorder (ADHD)
ES13726296T ES2621706T5 (es) 2012-04-18 2013-04-18 Diaminooxidasa para utilizar en el tratamiento o la prevención del trastorno por déficit de atención con hiperactividad (TDAH)
DK13726296.0T DK2844277T3 (en) 2012-04-18 2013-04-18 DIAMINOXIDASE TO USE IN TREATMENT OR PREVENTION OF DIFFICULTIES OF ATTENTION, ACTIVITY AND IMPULSIVITY (ADHD)
EP13726296.0A EP2844277B2 (en) 2012-04-18 2013-04-18 Diamine oxidase for use in the treatment or prevention of attention deficit hyperactivity disorder (adhd)
HUE13726296A HUE032712T2 (en) 2012-04-18 2013-04-18 Diamine oxidase for use in the treatment or prevention of attention deficit hyperactivity disorder (ADHD)
PT137262960T PT2844277T (pt) 2012-04-18 2013-04-18 Resumo
PL13726296T PL2844277T5 (pl) 2012-04-18 2013-04-18 Oksydaza diaminowa do stosowania w leczeniu lub zapobieganiu zespołowi nadpobudliwości z deficytem uwagi (ADHD)
CN201380020361.6A CN104284672A (zh) 2012-04-18 2013-04-18 用于治疗或预防注意力缺陷多动障碍(adhd)的二胺氧化酶
RU2014140676A RU2660344C2 (ru) 2012-04-18 2013-04-18 Диаминоксидаза для применения в лечении или предупреждении синдрома дефицита внимания с гиперактивностью (сдвг)
PCT/IB2013/053068 WO2013156955A1 (en) 2012-04-18 2013-04-18 Diamine oxidase for use in the treatment or prevention of attention deficit hyperactivity disorder (adhd)
MX2014012636A MX361227B (es) 2012-04-18 2013-04-18 Diaminooxidasa para usar en el tratamiento o la prevencion del trastorno por deficit de atencion con hiperactividad (tdah).

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201230578A ES2426539B1 (es) 2012-04-18 2012-04-18 Uso de la diaminooxidasa para el tratamiento o la prevención del trastorno por deficit de atencion con hiperactividad (adhd)

Publications (2)

Publication Number Publication Date
ES2426539A1 ES2426539A1 (es) 2013-10-23
ES2426539B1 true ES2426539B1 (es) 2014-09-09

Family

ID=48539331

Family Applications (2)

Application Number Title Priority Date Filing Date
ES201230578A Active ES2426539B1 (es) 2012-04-18 2012-04-18 Uso de la diaminooxidasa para el tratamiento o la prevención del trastorno por deficit de atencion con hiperactividad (adhd)
ES13726296T Active ES2621706T5 (es) 2012-04-18 2013-04-18 Diaminooxidasa para utilizar en el tratamiento o la prevención del trastorno por déficit de atención con hiperactividad (TDAH)

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES13726296T Active ES2621706T5 (es) 2012-04-18 2013-04-18 Diaminooxidasa para utilizar en el tratamiento o la prevención del trastorno por déficit de atención con hiperactividad (TDAH)

Country Status (11)

Country Link
US (1) US9795654B2 (es)
EP (1) EP2844277B2 (es)
CN (1) CN104284672A (es)
DK (1) DK2844277T3 (es)
ES (2) ES2426539B1 (es)
HU (1) HUE032712T2 (es)
MX (1) MX361227B (es)
PL (1) PL2844277T5 (es)
PT (1) PT2844277T (es)
RU (1) RU2660344C2 (es)
WO (1) WO2013156955A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12201676B2 (en) * 2011-03-18 2025-01-21 Dr Healthcare España, S.L. Composition comprising diamine oxidase for use in the treatment or prevention of fibromyalgia or chronic fatigue syndrome
EP4523700A1 (en) * 2023-09-14 2025-03-19 Dr Healthcare España, S. L. Diamine oxidase (dao) for use in the treatment and/or prevention of lower urinary tract symptoms (luts), overactive bladder (oab) symptoms and enuresis
EP4591876A1 (en) * 2024-01-25 2025-07-30 DR Healthcare S.L.U. Diamine oxidase (dao) for use in the treatment and/or prevention of sleep and circadian rhythm disorders, and cognitive impairment associated thereto

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6815177A (es) 1968-10-24 1970-04-28
GB1313318A (en) 1969-10-07 1973-04-11 Urbin M C Pharmaceutical preparation for the treatment of hemorrhoids
FR2101095A1 (en) 1970-08-20 1972-03-31 Merieux Inst Diamine oxidase from human placenta - for treatment of hyperhistamina
FR2215944A1 (en) 1973-02-01 1974-08-30 Bellon Labor Sa Roger Extracts of human placenta - free of proteases, and contg. histaminase, kininases and monoamine-oxidases for treating allergies
GB8319540D0 (en) 1983-07-20 1983-08-24 Bovril Ltd Amine removal
GB8325627D0 (en) 1983-09-24 1983-10-26 Scras Therapeutic compositions
US4725540A (en) 1984-07-09 1988-02-16 Emil Underberg Process for the preparation of amine-oxidase containing material, so produced amine-oxidase containing material
US4851243A (en) 1987-10-08 1989-07-25 Borden, Inc. Calcium fortified aseptically packaged milk
CH679582A5 (es) * 1988-07-18 1992-03-13 Glaxo Group Ltd
EP0557413A1 (en) 1990-10-31 1993-09-01 The Procter & Gamble Company Calcium fortified sauces
EP0818957A2 (en) 1995-04-07 1998-01-21 Abbott Laboratories Calcium supplements and calcium containing beverages comprising vitamin d
US5855936A (en) 1997-03-21 1999-01-05 Nestec S.A. Food fortification
ES2132037B1 (es) 1997-12-04 2000-03-16 Riu Juan Jose Duelo Diadema antimigrañosa.
US7232830B2 (en) 1998-06-26 2007-06-19 Elaine A Delack Method for treatment of neurodegenerative diseases and effects of aging
WO2000062812A1 (en) 1999-04-20 2000-10-26 Advocare International Llc Nutritional composition for improved cognitive performance
IT1317067B1 (it) 2000-11-29 2003-05-26 Univ Roma Istaminasi di origine vegetale nel trattamento dello shock allergico esettico e nell'asma allergico.
US20030124174A1 (en) 2001-10-25 2003-07-03 Endo Pharmaceuticals, Inc Method for treating non-neuropathic pain
US20050192290A1 (en) 2004-01-13 2005-09-01 Isaac Melamed Treatment of behavioral disorders
JP2007531753A (ja) * 2004-03-31 2007-11-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 非イミダゾール系複素環式化合物
US20060002913A1 (en) 2004-06-22 2006-01-05 Gehlsen Kurt R Use of histamine and related compounds to treat disorders affecting muscle function
AT502098B8 (de) * 2004-07-07 2007-06-15 Albert Dr Missbichler Diaminooxidase-hältige zusammensetzung
AT502850B1 (de) 2005-11-18 2007-08-15 Albert Dr Missbichler Verfahren zur bestimmung der aktivität von diaminooxidase
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
JP4585610B2 (ja) * 2007-01-22 2010-11-24 ファイザー・プロダクツ・インク 治療用化合物のトシル酸塩およびその医薬組成物
ES1064812Y (es) 2007-02-08 2007-08-01 Riu Juan Jose Duelo Dispositivo anti-migraña perfeccionado
EP2020446A1 (en) * 2007-07-31 2009-02-04 Denis Vincent Compositions and methods for detecting histamine related disorders
US20110236491A1 (en) 2010-03-25 2011-09-29 Jeannette Chantalat Topical anti-inflammatory composition
ES2388166B1 (es) 2011-03-18 2013-10-01 Dr Healthcare España, S. L. Alimentos funcionales que contienen diaminooxidasa y sus usos.
ES2388395B1 (es) 2011-03-18 2013-10-01 Dr Healthcare España, S. L. Uso de la diaminooxidasa para el tratamiento o la prevención de la fibromialgia o la fatiga crónica.
US20160024481A1 (en) 2011-03-18 2016-01-28 Dr Healthcare España, S.L. Topical compositions comprising diaminooxidase for the treatment or prevention of diseases associated with high histamine levels which involve an increase in pain
ES2388515B1 (es) 2011-03-18 2013-10-01 Dr Healthcare España, S. L. Uso de la diaminooxidasa para la prevención de los síntomas de la resaca.
US12201676B2 (en) 2011-03-18 2025-01-21 Dr Healthcare España, S.L. Composition comprising diamine oxidase for use in the treatment or prevention of fibromyalgia or chronic fatigue syndrome
ES2387973B1 (es) 2011-03-18 2013-10-01 Dr Healthcare España, S. L. Composiciones tópicas que contienen diaminooxidasa para el tratamiento o la prevención de enfermedades asociadas a un nivel de histamina elevada que comportan un aumento del dolor.

Also Published As

Publication number Publication date
EP2844277A1 (en) 2015-03-11
EP2844277B2 (en) 2020-03-25
DK2844277T3 (en) 2017-04-24
RU2660344C2 (ru) 2018-07-05
US9795654B2 (en) 2017-10-24
PT2844277T (pt) 2017-05-12
US20150093430A1 (en) 2015-04-02
EP2844277B1 (en) 2017-02-01
CN104284672A (zh) 2015-01-14
ES2621706T3 (es) 2017-07-04
MX2014012636A (es) 2015-01-15
ES2426539A1 (es) 2013-10-23
RU2014140676A (ru) 2016-06-10
HUE032712T2 (en) 2017-10-30
ES2621706T5 (es) 2021-01-08
PL2844277T3 (pl) 2017-09-29
PL2844277T5 (pl) 2020-07-13
MX361227B (es) 2018-11-29
WO2013156955A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
ES2644844T3 (es) Mecanismo de soporte
ES2643848T3 (es) Método para cuantificar dosis UV desinfectantes usando indicadores
ES2421956B1 (es) Nueva forma cristalina de sulfato de sitagliptina
GT201400033A (es) Pirimidinas anilladas sustituidas y uso de las mismas
CR20140576A (es) Sintesis de compuestos heterociclicos
EP2836628A4 (en) OXYORTHOSILICATE SCREENS BASED ON MULTIPLE DOTED LUTETIUM WITH IMPROVED PHOTONIC PROPERTIES
IT1400982B1 (it) Collirio osmotico trans-epiteliale per la cura del cheratocono.
PT2928477T (pt) Utilização do inibidor da telomerase imetelstat para o tratamento de mielofibrose.
JP2013132557A5 (es)
JP2012204203A5 (es)
MX377534B (es) Compuestos para usarse en el tratamiento de hiperinsulinemia.
CL2013002908A1 (es) Uso de compuestos derivados de bencimidazol-4-carboxamida para el tratamiento profilactico de la neuropatia periferica inducida por quimioterapia .
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
CU20160003A7 (es) Pirazololpiridinaminas sustituidas
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
EP2851931A4 (en) MICRO CHANNEL PLATE
IN2015DN00515A (es)
BR112013031702A2 (pt) 1-piperazino-3-fenil indanos deuterados para o tratamento de esquizofrenia
ES2426539B1 (es) Uso de la diaminooxidasa para el tratamiento o la prevención del trastorno por deficit de atencion con hiperactividad (adhd)
JP2014005521A5 (es)
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
JP2013081937A5 (es)
ES2536842T3 (es) Composición farmacéutica para el tratamiento del cáncer
PL2838529T3 (pl) Kompozycja zawierająca kwas alfa-liponowy i honokiol do leczenia neuropatii
JP2014020489A5 (es)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2426539

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20140909